Amarin (AMRN) vs CytomX Therapeutics (CTMX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Amarin (AMRN) has outperformed CytomX Therapeutics (CTMX) over the past year, losing 35.5% versus a loss of 47.7%. Over five years, CTMX leads with a -69.9% price change compared with -85.5% for AMRN. Amarin is the larger company by market cap ($444.4 million vs $442.5 million), about 1.0 times the size.
Amarin converts more of its revenue into profit, with a net margin of -18.2% versus -22.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AMRN | CTMX |
|---|---|---|
| Share price | $10.57 | $2.03 |
| Market cap | $444.39M | $442.55M |
| 1-day change | -6.13% | -0.98% |
| YTD return | -24.28% | -52.35% |
| 1-year return | -35.47% | -47.68% |
| 5-year return | -85.48% | -69.93% |
| Forward P/E | 10.79 | — |
| EPS (TTM) | $-0.80 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $213.65M | $76.20M |
| Revenue growth (YoY) | -6.55% | -44.82% |
| Net income (latest FY) | $-38.80M | $-17.37M |
| Gross margin | 56.57% | — |
| Operating margin | -23.48% | -29.35% |
| Net margin | -18.16% | -22.79% |
| 52-week high | $17.31 | $8.21 |
| 52-week low | $10.56 | $1.87 |
| Distance from 52-week high | -38.94% | -75.27% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +22.99% | +509.85% |
| Average volume | 79.50K | 4.27M |
| Shares outstanding | 42.04M | 218.00M |
| Employees | 80 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AMRN has outperformed CTMX by 12.2 percentage points over the past year.
- Amarin grew revenue faster in its latest fiscal year (-6.55% vs -44.82%).
About Amarin
AMRN stock →Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. It offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 80 employees
About CytomX Therapeutics
CTMX stock →CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
AMRN vs CTMX FAQ
Which is bigger, Amarin or CytomX Therapeutics?
Amarin (AMRN) is larger, with a market capitalization of $444.39M compared with $442.55M for CytomX Therapeutics (CTMX).
Which stock has performed better over the past year, AMRN or CTMX?
AMRN returned -35.47% over the past 12 months, compared with -47.68% for CTMX (price return, excluding dividends). Past performance does not predict future results.
Are Amarin and CytomX Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.